Publication | Open Access

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Gastrointestinal OncologyMedicineBiliary CancerPharmacologyPathologyChemotherapy-refractory CholangiocarcinomaMolecular OncologyBiliary CancersCancer TreatmentOncologyCancer Research